Democratic People's Republic of Korea vs Eritrea: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Democratic People's Republic of Korea
0.4%
in 2024
Eritrea
0.5%
in 2024
Democratic People's Republic of Korea rank
74th
Eritrea rank
71st
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Democratic People's Republic of Korea
- Eritrea
How they compare
Eritrea currently reports 0.5% against 0.4% in Democratic People's Republic of Korea, a difference of 0.1%.
That makes Eritrea's figure about 1.2 times Democratic People's Republic of Korea's.
Across all 10 years both countries report, Eritrea has been ahead every year.
Democratic People's Republic of Korea ranks 74th and Eritrea ranks 71st of 246 countries.
Eritrea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Democratic People's Republic of Korea | Eritrea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.4% | 0.6% | 0.2% | Eritrea |
| 2020s | 0.3% | 0.6% | 0.3% | Eritrea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Democratic People's Republic of Korea or Eritrea?
- Eritrea, at 0.5% against 0.4% in Democratic People's Republic of Korea as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Democratic People's Republic of Korea and Eritrea?
- 0.1%, with Eritrea ahead.
- How many years of comparable data are there for Democratic People's Republic of Korea and Eritrea?
- 10 years are reported by both, from 2015 to 2024.
- How do Democratic People's Republic of Korea and Eritrea rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Democratic People's Republic of Korea ranks 74th and Eritrea ranks 71st of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.